Propolis Carnosic Acid Synergy Against Cryptococcus
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for fungal infections, particularly those caused by opportunistic fungi like Cryptococcus neoformans, are ineffective due to the difficulty in achieving high selective toxicity and the emergence of resistant strains, leading to prolonged healing times and high mortality rates, especially in immunocompromised patients.
Innovation Solution
A synergistic composition of propolis and carnosic acid, with propolis containing 70-90% polyphenols and carnosic acid at concentrations above 70%, is used to treat infections such as cryptococcal meningitis and pneumonia, demonstrating a synergistic effect that exceeds the sum of individual compound actions, as proven by kinetic and dose-response assays.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antifungal agents are used to treat Cryptococcus neoformans infections, then the treatment can be administered, but the therapeutic effect is insufficient due to low selective toxicity and emergence of resistant strains
Solution Approach 1:
The patent combines propolis and carnosic acid into a synergistic composition where the interaction between the two substances produces a therapeutic effect greater than the sum of their individual effects. This combination overcomes the limitations of single antifungal agents by creating a multi-target approach that reduces resistance development while enhancing selective toxicity against Cryptococcus neoformans.
Solution Approach 2:
The invention creates a composite therapeutic formulation integrating propolis (a natural bee product with antimicrobial properties) and carnosic acid (a phenolic compound). This composite material leverages the complementary mechanisms of action of both components to achieve superior antifungal activity against Cryptococcus neoformans compared to conventional single-agent therapies.
2Reliability
If conventional antifungal treatments are used, then treatment can be provided, but the healing time is prolonged due to the persistence of fungal infections in the human body
Solution Approach 1:
By merging propolis and carnosic acid into a synergistic composition, the treatment achieves rapid and potent antifungal activity that significantly reduces the persistence of Cryptococcus neoformans infections. The synergistic interaction accelerates pathogen elimination, thereby shortening the prolonged healing times associated with conventional antifungal therapies.
3Device complexity
If single substance formulations are used, then the treatment is simple, but the therapeutic effect does not exceed the individual sum of actions
Solution Approach 1:
The patent applies the merging principle by combining propolis and carnosic acid in a formulation where their interaction generates synergistic effects. This means the therapeutic outcome exceeds the simple sum of individual substance actions, achieving enhanced efficacy while maintaining relative formulation simplicity through the use of two well-defined active components.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Synergistic composition comprising propolis comprising polyphenols at a concentration between 70 and 90% by weight with respect to propolis and carnosic acid, for use thereof for preventing and/or treating infections caused by the species of the opportunistic fungus Cryptococcus neoformans such as cryptococcosis, meningitis and pneumonia in humans and/or in animals, pharmaceutical composition, veterinarian composition and food product related thereto.